Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Novanta Inc Q1 2026 Earnings Call - Bookings Surge 37% as AI and Medical Tech Drive Broad-Based Momentum
Novanta delivered a sharp turn in momentum in Q1 2026, with organic revenue growth accelerating to 3% and bookings jumping 37% year-over-year. The company is riding a broad-based wave of demand across...
- Bookings surged 37% year-over-year with a book-to-bill ratio of 1.10, signaling robust demand across all business units and setting the stage for accelerated revenue growth.
- Organic revenue growth accelerated to 3% in Q1 2026, with management raising full-year guidance to expect organic growth of up to 6%, reflecting a clear inflection in momentum.
- New product revenue jumped 50% year-over-year, and design wins were up nearly 30%, validating the company’s innovation-driven strategy and sticky OEM partnerships.
- +7 more takeaways
Ambiq Micro Q1 2026 Earnings Call - Edge AI Demand Outpaces Supply, Diversification Gains Traction
Ambiq Micro delivered a sharp start to 2026, with Q1 net sales of $25.1 million beating guidance and rising 59% year-over-year. The growth was driven by broad-based demand for edge AI across wearables...
- Q1 2026 net sales reached $25.1 million, up 59.3% year-over-year and beating guidance, driven by strong demand for edge AI across wearables and new markets.
- Over 80% of Ambiq’s units now run AI algorithms, with demand accelerating across form factors including watches, rings, and smart eyewear.
- The company successfully diversified its customer base, reducing the revenue share of its top three customers from 86% in Q1 2025 to 71% in Q1 2026.
- +7 more takeaways
Millicom Q1 2026 Earnings Call - Coltel Integration and Chile Turnaround Drive Record Cash Flow
Millicom delivered a robust Q1 2026, driven by the consolidation of Coltel in Colombia and the successful application of its turnaround playbook in Ecuador and Uruguay. Reported service revenue surged...
- Reported service revenue jumped 45% YoY to $1.9 billion, driven by the consolidation of Coltel; organic service revenue growth remained a healthy 4.9%.
- Adjusted EBITDA reached $857 million with a 43.2% margin; excluding Coltel, the margin expanded to 47.9%, highlighting underlying operational strength.
- Equity free cash flow hit a record Q1 of $225 million, up 66% year-over-year, supported by disciplined cost management and FX tailwinds.
- +7 more takeaways
Silvercrest Asset Management Q1 2026 Earnings Call - Heavy Investment Costs Weigh on Margins Amid Global Expansion
Silvercrest Asset Management entered its 25th year with a clear strategic pivot toward global expansion, but the Q1 2026 financials reflect the heavy price tag of that ambition. Discretionary AUM fell...
- Discretionary AUM declined 3.7% sequentially to $23.1 billion, driven by net institutional outflows, though year-over-year discretionary AUM grew nearly 2%.
- Total AUM increased 1.1% year-over-year to $35.7 billion, with management noting a future accounting change will lower non-discretionary AUM reporting without impacting revenue.
- Revenue remained flat at $31.4 million year-over-year, while expenses rose 13.5% to $22.4 million, primarily due to increased compensation and administrative costs.
- +9 more takeaways
NET Power Q1 2026 Earnings Call - Commercial Offtake Process Gating Capital Commitment for Permian Phase I
NET Power is pivoting hard from engineering to commercialization, making the offtake process for Project Permian Phase I the single most critical milestone. The company is holding back on major capita...
- NET Power is prioritizing commercial offtake agreements as the gating condition for project financing and capital deployment for Project Permian Phase I.
- The company has $319 million in cash and no debt, providing ample runway to reach final investment decision while maintaining a low quarterly burn rate of $8 million to $9 million.
- Project Permian Phase I targets 80 MW net output with over 90% CO2 capture, sited in West Texas with plans to scale to 800 MW on the same acreage.
- +7 more takeaways
Solesence Q1 2026 Earnings Call - Gross Margins Expand as Operational Overhaul Drives Near-Term Revenue Miss
Solesence reported a revenue decline to $13 million in Q1 2026, a clear miss driven by On-Time In-Full (OTIF) execution failures during its transition to a new supply chain model. The company’s pivot ...
- Revenue declined 11% year-over-year to $13 million, down from $14.6 million in Q1 2025, primarily due to On-Time In-Full (OTIF) shipment delays rather than a drop in customer demand.
- Gross margin expanded by 300 basis points to 26%, driven by improved labor efficiency and the elimination of product quality-related waste that plagued the prior year.
- Net income swung to a $0.8 million loss from a $0.08 million profit in the prior year, reflecting near-term investments in operational infrastructure and organizational realignment.
- +9 more takeaways
Pattern Q1 2026 Earnings Call - Record 127% Net Revenue Retention Drives Raised Guidance
Pattern delivered a record first quarter for 2026, with revenue surging 43% year-over-year to $774 million and adjusted EBITDA climbing 59% to $54 million. The company raised its full-year revenue out...
- Revenue grew 43% year-over-year to $774 million in Q1 2026, exceeding prior expectations and validating the company’s growth trajectory.
- Adjusted EBITDA reached $54 million, up 59% year-over-year, driven by revenue expansion and operating leverage across sales, marketing, and operations.
- Net revenue retention (NRR) hit a record 127%, up from 115% in the prior year, reflecting strong existing brand partner growth and platform stickiness.
- +7 more takeaways
Novo Nordisk Q1 2026 Earnings Call - Wegovy Pill Uptake Offsets Price Erosion
Novo Nordisk’s Q1 2026 results reveal a company navigating a complex pricing environment while accelerating its commercial momentum. Adjusted sales fell 4% due to lower realized prices, but volume gro...
- Adjusted sales declined 4% due to lower realized prices, partially offset by GLP-1 volume growth and market expansion.
- Wegovy pill achieved record-breaking uptake, exceeding 1 million patients in just 16 weeks post-launch in the U.S.
- The Wegovy franchise now holds approximately 65% new-to-brand (NBRX) market share in the U.S. anti-obesity medication space.
- +7 more takeaways
Bioceres Crop Solutions Q3 FY2026 Earnings Call - ProFarm Foreclosure and Litigation Dominate Financials
Bioceres Crop Solutions faced a turbulent fiscal third quarter, overshadowed by the foreclosure of its ProFarm business and ongoing litigation with secured note holders. The company reported a net los...
- Total revenues declined 23% year-over-year to $39.4 million, with Crop Protection down 18% and Seed/Integrated Products down 71% due to strategic phasing out of low-margin seed sales.
- Crop Nutrition was the sole growth segment, rising 15% year-over-year to $11.6 million, driven by strong demand for microbial fertilizers amid global supply uncertainties.
- Gross profit fell 30% to $12.7 million, with a 38% decline in Crop Nutrition primarily due to a non-recurring inoculant obsolescence adjustment.
- +7 more takeaways
AECOM Q2 2026 Earnings Call - Record Backlog and Raised Guidance Driven by AI Wins and Defense Spending
AECOM delivered a second quarter of record-breaking execution, pushing adjusted EBITDA and adjusted EPS to new highs while expanding its backlog to an all-time level. The company raised full-year guid...
- Full-year adjusted EPS and EBITDA guidance raised to 14% and 7% growth respectively, marking the second upward revision this year.
- Record backlog reached new highs, driven by a 1.2x design book-to-burn ratio and robust win rates across the Americas and International segments.
- Americas design business drove 8% net service revenue growth, with segment adjusted operating margins expanding 60 basis points to 20%.
- +7 more takeaways